Key result
Hyperpolypharmacy was present in 26% of adults with heart failure and was independently associated with low household income (PR 1.70) and low educational status (PR 1.74).
Why the study?
Expanding pharmacologic therapies for heart failure have increased medication burden, but the prevalence and determinants of hyperpolypharmacy (≥10 medications) remained uncharacterized.
Population
947 adults aged ≥50 years with self-reported HF from NHANES 2003-2014
Comparison
Hyperpolypharmacy (≥10 medications) vs <10 medications
Design
Observational cross-sectional survey study
Authors
Loading...
Should not yet change practice; leaves open whether addressing income and education reduces hyperpolypharmacy in heart failure.
Cross-Sectional (n=947)
Relative Risk: 1.7 (95% CI 1.01–2.85)
p-value: p=0.04
Hyperpolypharmacy (taking ≥10 medications) is highly prevalent (26%) among older adults with heart failure and is independently associated with non-medical factors such as low income and low education.
Kennel et al. (2019) conducted a cross-sectional in Heart failure (n=947). Low household income (<$20,000) vs. Household income ≥$75,000 was evaluated on Hyperpolypharmacy (≥10 medications) (PR 1.70, 95% CI 1.01-2.85, p=0.04). Hyperpolypharmacy was present in 26% of adults with heart failure and was independently associated with low household income (PR 1.70) and low educational status (PR 1.74).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: